In last trading session, ATAI Life Sciences N.V. (NASDAQ:ATAI) saw 1.44 million shares changing hands with its beta currently measuring 0.79. Company’s recent per share price level of $1.28 trading at $0.08 or 6.67% at ring of the bell on the day assigns it a market valuation of $214.78M. That closing price of ATAI’s stock is at a discount of -122.66% from its 52-week high price of $2.85 and is indicating a premium of 20.31% from its 52-week low price of $1.02. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.6 million shares which gives us an average trading volume of 570.06K if we extend that period to 3-months.

For ATAI Life Sciences N.V. (ATAI), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.16 in the current quarter.

ATAI Life Sciences N.V. (NASDAQ:ATAI) trade information

Upright in the green during last session for gaining 6.67%, in the last five days ATAI remained trading in the green while hitting it’s week-highest on Friday, 10/18/24 when the stock touched $1.28 price level, adding 5.88% to its value on the day. ATAI Life Sciences N.V.’s shares saw a change of -9.22% in year-to-date performance and have moved 16.36% in past 5-day. ATAI Life Sciences N.V. (NASDAQ:ATAI) showed a performance of 1.59% in past 30-days. Number of shares sold short was 9.48 million shares which calculate 21.01 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 78.67% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -368.75% in reaching the projected high whereas dropping to the targeted low would mean a loss of -368.75% for stock’s current value.

ATAI Life Sciences N.V. (ATAI) estimates and forecasts

Statistics highlight that ATAI Life Sciences N.V. is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -30.81% of value to its shares in past 6 months, showing an annual growth rate of -212.00% while that of industry is 17.10. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 43.30% from the last financial year’s standing.

And 4 analysts are in estimates of company making revenue of 370k in the next quarter. Company posted 87k and 18k of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 44.19% during past 5 years.

ATAI Life Sciences N.V. (NASDAQ:ATAI)’s Major holders

Insiders are in possession of 9.99% of company’s total shares while institution are holding 27.09 percent of that, with stock having share float percentage of 30.09%. Investors also watch the number of corporate investors in a company very closely, which is 27.09% institutions for ATAI Life Sciences N.V. that are currently holding shares of the company. WALLEYE CAPITAL LLC is the top institutional holder at ATAI for having 2.76 million shares of worth $3.67 million. And as of 2024-06-30, it was holding 1.7388 of the company’s outstanding shares.

The second largest institutional holder is MORGAN STANLEY, which was holding about 2.72 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.7111 of outstanding shares, having a total worth of $3.62 million.